Accustem Sciences (ACUT) Retained Earnings (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Retained Earnings of $6.4 million for Q1 2026, up 175.35% year-over-year from $2.3 million in Q1 2025, and little changed quarter-over-quarter from $6.4 million in Q4 2025.
Accustem Sciences (ACUT) Retained Earnings (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Retained Earnings for 6 consecutive years, with $6.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 175.35% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (up 175.35% YoY), while the FY2025 annual figure was $6.4 million, up 179.3% from the prior year.
- Retained Earnings held at $6.4 million in Q1 2026 per ACUT's latest filing, from $6.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $6.4 million in Q1 2026 and bottomed at -$8.9 million in Q2 2025.
- Historically, Retained Earnings has averaged -$220055.4 across 5 years, with a median of $4.2 million in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 696.03% — and 2025, when it tumbled 300.15%.
- Accustem Sciences' Retained Earnings stood at $4.3 million in 2022, then climbed by 1.82% to $4.4 million in 2023, then plunged by 282.47% to -$8.0 million in 2024, then jumped by 179.3% to $6.4 million in 2025, then grew by 0.24% to $6.4 million in 2026.
- Business Quant data shows ACUT's Retained Earnings at $6.4 million in Q1 2026, $6.4 million in Q4 2025, and $6.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 4.38 Bn |
| 10 | Accustem Sciences | 2.60 Mn | 2.59 Mn | - | -10.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.38 Mn |
| Dec 31, 2025 | 6.37 Mn |
| Sep 30, 2025 | 6.34 Mn |
| Jun 30, 2025 | -8.87 Mn |
| Mar 31, 2025 | -8.47 Mn |
| Dec 31, 2024 | -8.03 Mn |
| Sep 30, 2024 | -7.65 Mn |
| Jun 30, 2024 | 4.43 Mn |
| Mar 31, 2024 | 4.42 Mn |
| Dec 31, 2023 | 4.40 Mn |
| Sep 30, 2023 | 4.38 Mn |
| Jun 30, 2023 | -5.68 Mn |
| Mar 31, 2023 | -5.30 Mn |
| Dec 31, 2022 | 4.32 Mn |
| Sep 30, 2022 | -3.49 Mn |
| Jun 30, 2022 | 4.23 Mn |
| Mar 31, 2022 | -1.52 Mn |
| Dec 31, 2021 | -724,862.00 |